Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease

Neurophysiologie Clinique

Volumn 31, Issue 5, 2001, Pages 321-340

  Thobois, S ^a   Guillouet, S ^a   Broussolle, E ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Activation; Caudate nucleus; Cerebral blood flow (rCBF); Cerebral metabolism; Dopamine; Parkinson's disease; Parkinsonism; Positron emission tomography (PET); Putamen; Regional; Single photon emission computed tomography (SPECT); Striatum; 11C Raclopride; 123I FP CIT; 123 CIT; 15O H2O; 18F desoxyglucose; 18F fluoro L Dopa

Indexed keywords

CARBON 11; DOPAMINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; IODINE 123; RACLOPRIDE; TROPANE DERIVATIVE;

BRAIN METABOLISM; CAUDATE NUCLEUS; DOPAMINERGIC SYSTEM; DYSTONIA; HEMODYNAMICS; HUMAN; NEUROCHEMISTRY; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGING; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BRAIN TISSUE TRANSPLANTATION; CELL TRANSPLANTATION; CEREBROVASCULAR CIRCULATION; DIAGNOSIS, DIFFERENTIAL; DIHYDROXYPHENYLALANINE; DOPAMINE AGONISTS; ELECTRIC STIMULATION THERAPY; FETAL TISSUE TRANSPLANTATION; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IATROGENIC DISEASE; IMAGINATION; LIGANDS; MESENCEPHALON; MOTOR ACTIVITY; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PARKINSONIAN DISORDERS; RADIOPHARMACEUTICALS; RATS; RECEPTORS, DOPAMINE; RISK; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREMOR;

EID: 0035155365     PISSN: 09877053     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0987-7053(01)00273-8     Document Type: Review

References (160)

1. The biochemistry of Parkinson's disease
2. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing
3. Effect of age on D2-dopamine receptors in normal human brain measured by positron emission tomography and 11 C-Raclopride
4. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease
5. Brain muscarinic receptors in progresive supranuclear palsy and Parkinson's disease: A positron emission tomographic study
6. 123I]-β-CIT and SPECT in essential tremor and Parkinson's disease
7. Dopa-responsive dystonia: A clinical and molecular genetic study
8. Loss of striatal [76Br] bromospiperone binding sites demonstrated by positron emission tomography in progressive supranuclear palsy
9. 123I]-FP-CIT study group
10. Positron emission tomography study in porgressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations
11. Does frontal cortex hypometabolism in progressive supranuclear palsy result from subcortical dysfunction?
12. Corticobasal degeneration: Decreased and asymmetrical glucose consumption as studied with PET
13. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
14. Imaging the dopaminergic neurotransmission system using singlephoton emission tomography and positron emission tomography in patients with parkinsonism
15. PET studies in progressive supranuclear palsy
16. PET and SPECT studies in Parkinson's disease
17. The early diagnosis of Parkinson's disease
18. 18F-Dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
19. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET
20. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-Raclopride and positron emission tomography
21. A comparison of the abnormal patterns of cerebral activation associated with neuropathic and essential tremor
22. Isolated tremor and disruption of the nigrostriatal dopaminergic system: An 18F-dopa PET study
23. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease
24. Fréquence et profil clinique des formes familiales de maladie de Parkinson. Enquête portant sur 428 cas-index recrutés dans un service de neurologie
25. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease
26. 18F]-Dopa PET study in patients with juvenile-onset Parkinson's disease and parkin gene mutations
27. 123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy
28. Dopamine D2 receptor imaging with SPECT. Studies in different neuropsychiatric disorders
29. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics
30. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side-effects. A SPECT study
31. 18F-Dopa PET study
32. 18F-dopa PET data
33. Positron emission tomography after MPTP: Observations relating to the cause of Parkinson's disease
34. Preliminary report: Activation of the cerebellum in essential tremor
35. Age-dependant decline of nigrostriatal dopaminergic function: A positron emission tomographic study of grandparents and their children
36. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms
37. Subcortical dementia. Frontal cortex hypometabolism detected by positron emission tomography in patients with progressive supranuclear plasy
38. The neurophysiological basis of motor imagery
39. Thalamic stimulation and suppression of parkinsonian tremor: Evidence of a cerebellar deactivation using positron emission tomography
40. Striatal D2 dopamine receptor status in Parkinson's disease. A [18F]-Dopa and [11C]raclopride PET study
41. Decreased glucose utilisation in the striatum and frontal lobe in probable striatonigral degeneration
42. Motor imagery of a lateralized sequential task is asymmetrically slowed in hemi-Parkinson patients
43. Glucose hypermetabolism of the inferior olive in patients with essential tremor
44. Cognitive deficits in Parkinson's disease
45. The metabolic landscape of cortico-basal ganglionic degeneration: Regional asymmetries studied with positron emission tomography
46. The metabolic topography of parkinsonism
47. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease
48. Striatal [18F]-Dopa uptake: Absence of an aging effect
49. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease
50. Dopamine autoreceptor function is lost in advanced Parkinson's disease
51. Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β(4′iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2βcarbomethoxy-βg- (3′,4′-disubstituted phenyl) nortropane. New high affinity and selective compounds for the dopamine transporter
52. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine
53. Striatonigral degeneration: A clinico-pathological study
54. Updating the functional model of the basal ganglia
55. Cerebral hypometabolism in progressive supranuclear plasy studied with positron emission tomography
56. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
57. Corticobasal degeneration: Neuropsychological assessment and dopamine D2 receptor SPECT analysis
58. Association between essential tremor and Parkinson's disease
59. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease
60. Corticobasal degeneration
61. Effect of reserpine-induced depletion of synaptic dopamine on [11C]raclopride binding to D2-dopamine receptors in the monkey brain
62. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy
63. Magnetic resonance imaging of corticobasal degeneration
64. A selective radiobrominated cocaine analogue for imaging of dopamine uptake sites: Pharmacological evaluation and PET experiments
65. Parkinsonism: Onset, progression and mortality
66. Functional effects of striatal dysfunction in Parkinson's disease
67. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases
68. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease
69. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-Fdopa/PET
70. Self-initiated versus externally triggered movements. 1. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects
71. Progressive supranuclear palsy: Clinico-pathological and biochemical studies
72. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine
73. 123I]β-CIT single photon emission tomography is normal in dopa-responsive dystonia
74. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease
75. Stability of (123I)IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans
76. Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of Parkinson's disease
77. Evidence for striatal dopamine release during a video game
78. Tremors in early Parkinson's disease
79. Neuropathological evidence of graft survival and striaral reinnervation after transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease
80. Patterns of cerebral glucose utilisation determined in Parkinson's disease by the 18Ffluorodeoxyglucose method
81. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
82. Parkinson's disease. 1st of two parts
83. Parkinson's disease. 2nd of two parts
84. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
85. The definition of multiple system atrophy: A review of recent developments
86. Cellular pathology of multiple system atrophy
87. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration
88. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
89. Steele-RichardsonOlszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography
90. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography
91. The effect of L-Dopa on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease
92. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease
93. Evidence for long term survival and function of dopaminergic grafts in progressive Parkinson's disease
94. Accuracy of the clinical diagnosis of corricobasal degeneration: A clinicopathologic study
95. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steel-Richardson-Olszewski syndrome)
96. Progressive supranuclear palsy
97. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome
98. Contribution of PET studies in diagnosis of corticobasal degeneration
99. Relationship between striatal dopamine denervation and frontal executive tests in Parkinson's disease
100. 123I]βCIT in Parkinson's disease and progressive supranuclear palsy evaluated with single-photon emission tomography
101. L-Dopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements
102. 18F]dopa PET
103. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration
104. 18F]CFT
105. Dopa-responsive dystonia: Long-term treatment response and prognosis
106. Evidence for a common network of brain structures involved in parkinsonian tremor and voluntary repetitive movement
107. Dopamine D1 and D2 receptors in progressive supranuclear palsy: An autoradiographic study
108. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
109. The role of inheritance in sporadic Parkinson's disease. Evidence from a longitudal study of doparminergic function in twins
110. 18F-Dopa PET study
111. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias
112. Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study
113. Multiple system atrophy - The nature of the beast
114. Dopa-responsive dystonia: Pathological and biochemical observations in a case
115. Clinicopathologic observations in essential tremor: Report of six cases
116. 18F]dopa-PET study
117. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia
118. Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine
119. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa
120. The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients
121. Corticodendatonigral degeneration with neuronal achromasia
122. 18F]fluorodopa uptake in five grafted parkinsonian patients
123. Cortical-basal ganglionic degeneration
124. PET demonstrates different behavior of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease
125. Cognitive imapirment and the brain dopaminergic system in Parkinson's disese
126. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OH-DA lesion of the substantia nigra: A microdialysis study in freely moving rats
127. Motor dysfunction in olivopontocerebellar atrophy is related to cerebral metabolic rate studies with position emission tomography
128. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease
129. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects
130. Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanism
131. Problems in the differential diagnosis of essential tremor
132. PET studies of parkinsonism associated with mutation in the α-synuclein gene
133. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study
134. 15O PET study
135. SPECT findings in Parkinson's disease associated with dementia
136. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography
137. Striatal function in normal aging: Implications for Parkinson's disease
138. 18F]Dopa positron emission tomography
139. 123I-iodobenzamide-SPECT predicts dopaminergic responsivness in patients with de-novo parkinsonism
140. Decreased SPECT 123Iβ-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease
141. Age correlated loss of dopaminergic binding sites in human basal ganglia
142. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: A positron emission tomography study
143. Positron emission tomographic studies of Dopa-responsive dystonia and early-onset idiopathic parkinsonism
144. 18F]Fluorodopa studies correlate with dopamine cell counts and levels
145. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism
146. The [14C]-deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure and normal values in the conscious and anesthetized albino rat
147. Overactivation of primary motor cortex is asymmetrical in hemiparkinsonian patients: A PET study
148. Motor imagery in normal subjects and in parkinsonian patients with asymmetric akinesia: A PET study
149. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease
150. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias
151. 123I-IBZM single photon emission computed tomography
152. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
153. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions
154. Clinical features and natural history of multiple system atrophy
155. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease
156. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease
157. Effects of age on dopamine and serotonine receptors measured by positron emission tomography in the living human brain
158. In vivo measurement of dopamine receptors in human brain by positron emission tomography: Age and sex differences. Central determinants of age-related declines in motor function
159. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage